Streptozocin
Zanosar (streptozocin) is a small molecule pharmaceutical. Streptozocin was first approved as Zanosar on 1982-05-07. It is used to treat colorectal neoplasms, hodgkin disease, and islet cell carcinoma in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Zanosar
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Streptozocin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ZANOSAR | Teva | N-050577 RX | 1982-05-07 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| zanosar | New Drug Application | 2023-04-24 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9320 | Injection, streptozocin, 1 gram |
Clinical
Clinical Trials
133 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 15 | 44 | 29 | 13 | 26 | 124 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | — | 3 | 4 | 1 | 8 |
| Hiv | D006678 | O98.7 | — | — | 1 | 4 | — | 5 | |
| Hepatitis | D006505 | HP_0012115 | K75.9 | — | — | — | 1 | — | 1 |
| Exanthema | D005076 | R21 | — | — | — | 1 | — | 1 | |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | — | 1 | — | 1 |
| Hiv-associated lipodystrophy syndrome | D039682 | EFO_1001348 | — | — | — | 1 | — | 1 | |
| Lipodystrophy | D008060 | E88.1 | — | — | — | 1 | — | 1 | |
| Aids-related opportunistic infections | D017088 | — | — | — | 1 | — | 1 | ||
| Hemophilia a | D006467 | EFO_0007267 | D66 | — | — | — | 1 | — | 1 |
Show 2 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Aids-associated nephropathy | D016263 | EFO_0007313 | — | — | 1 | — | — | 1 | |
| Lactic acidosis | D000140 | EFO_1000036 | E87.20 | — | 1 | 1 | — | — | 1 |
| Aids dementia complex | D015526 | EFO_0002608 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 1 | — | — | — | — | 1 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cryptococcal meningitis | D016919 | EFO_0007228 | B45.1 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | STREPTOZOCIN |
| INN | streptozocin |
| Description | Streptozocin is an N-nitrosourea that is an antibiotic produced by Streptomyces achromogenes. It is used as an antineoplastic agent and to induce diabetes in experimental animals. It has a role as an antineoplastic agent, an antimicrobial agent, a DNA synthesis inhibitor and a metabolite. It is a N-acylglucosamine and a member of N-nitrosoureas. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CN(N=O)C(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O |
Identifiers
| PDB | — |
| CAS-ID | 18883-66-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1651906 |
| ChEBI ID | — |
| PubChem CID | 29327 |
| DrugBank | DB00428 |
| UNII ID | 5W494URQ81 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7,894 documents
View more details
Safety
Black-box Warning
Black-box warning for: Zanosar
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
6,426 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more